Free tool
FAERS Monitor: Lupron Depot
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020011 or its brand name (Lupron Depot, Leuprolide Acetate). Reports on generic versions are filed under their own applications.
Reports
29,123
Serious
17,188
59% of reports
Hospitalization
6,639
Death reported
4,144
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hot flush3,487
- death2,333
- fatigue1,923
- headache1,462
- pain1,285
- drug ineffective1,187
- nausea1,180
- arthralgia1,082
- asthenia998
- abdominal pain942
- off label use938
- vaginal haemorrhage878
- dizziness870
- fall837
- insomnia776
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 127 |
| 2005 | 119 |
| 2006 | 106 |
| 2007 | 141 |
| 2008 | 506 |
| 2009 | 978 |
| 2010 | 1,324 |
| 2011 | 1,582 |
| 2012 | 1,181 |
| 2013 | 1,670 |
| 2014 | 2,641 |
| 2015 | 2,663 |
| 2016 | 1,865 |
| 2017 | 1,342 |
| 2018 | 1,384 |
| 2019 | 1,495 |
| 2020 | 1,350 |
| 2021 | 1,527 |
| 2022 | 1,854 |
| 2023 | 1,614 |
| 2024 | 1,500 |
| 2025 | 1,148 |
| 2026 | 1,006 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,025,036 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hot flushSignal | 3,487 | 35.0 | 33.9 | 110,159 |
| vaginal haemorrhageSignal | 878 | 14.9 | 13.9 | 11,155 |
| abdominal painSignal | 942 | 2.9 | 2.8 | 1,206 |
| insomniaSignal | 776 | 2.1 | 2.0 | 455 |
| death | 2,333 | 2.0 | 1.9 | 1,137 |
| asthenia | 998 | 1.9 | 1.8 | 445 |
| arthralgia | 1,082 | 1.9 | 1.8 | 454 |
| fall | 837 | 1.8 | 1.7 | 312 |
| fatigue | 1,923 | 1.8 | 1.7 | 688 |
| headache | 1,462 | 1.7 | 1.6 | 419 |
| pain | 1,285 | 1.5 | 1.4 | 228 |
| dizziness | 870 | 1.3 | 1.2 | 48 |
| nausea | 1,180 | 1.1 | 1.0 | 7 |
| off label use | 938 | 0.8 | 0.7 | 65 |
| drug ineffective | 1,187 | 0.7 | 0.6 | 238 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.